EUS-guided gastroenterostomy versus duodenal self-expandable metal stent for malignant gastric outlet obstruction: results from a nationwide multicenter retrospective study (with video)

التفاصيل البيبلوغرافية
العنوان: EUS-guided gastroenterostomy versus duodenal self-expandable metal stent for malignant gastric outlet obstruction: results from a nationwide multicenter retrospective study (with video)
المؤلفون: Rubén Sánchez-Aldehuelo, José Carlos Subtil Iñigo, Belén Martínez Moreno, Joan Gornals, Carlos Guarner-Argente, Alejandro Repiso Ortega, Sandra Peralta Herce, José Ramón Aparicio, Enrique Rodríguez de Santiago, Sergio Bazaga, Diego Juzgado, Fernando González-Panizo, Agustín Albillos, Enrique Vázquez-Sequeiros
المصدر: Gastrointestinal Endoscopy. 96:1012-1020.e3
بيانات النشر: Elsevier BV, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Pancreatic Neoplasms, Gastric Outlet Obstruction, Self Expandable Metallic Stents, Gastroenterology, Humans, Stents, Radiology, Nuclear Medicine and imaging, Prospective Studies, Gastroenterostomy, Retrospective Studies
الوصف: Traditionally, palliative treatment of malignant gastric outlet obstruction (GOO) has been surgical, but surgical treatment carries significant morbidity and mortality rates. Endoscopic placement of a duodenal self-expandable metal stent (D-SEMS) has been proven to be successful for this indication in the short term. However, D-SEMSs are likely to malfunction over time. EUS-guided gastroenterostomy (EUS-GE) may help overcome these limitations. We aimed to evaluate stent failure-free survival at 3 months.A nationwide multicenter, observational study of D-SEMS and EUS-GE procedures for patients with malignant GOO was conducted at 7 academic centers from January 2015 to June 2020. Stent failure-free survival at 1, 3, and 6 months; technical and clinical success; adverse events (AEs); and patient survival were evaluated in both groups and compared.Ninety-seven patients were included in the D-SEMS group and 79 in the EUS-GE group. Pancreatic cancer was the main underlying malignancy in 53.4%. No statistically significant differences regarding technical (92.8% vs 93.7%) or clinical success (83.5% vs 92.4%) were found. AE rates did not differ between groups (10.3% vs 10.1%), although 2 events in the EUS-GE group required surgical management. Patients in the EUS-GE group had improved stent patency when compared with those patients in the D-SEMS group at 3 months (92.23% vs 80.6%; adjusted hazard ratio, .37; P = .033).EUS-GE seems to have improved patency outcomes when compared with D-SEMS placement for palliative treatment of malignant GOO. Prospective trials are needed to fully compare their efficacy and AE profile.
تدمد: 0016-5107
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d32d9e1faa11dc016befcd399fb6dc3
https://doi.org/10.1016/j.gie.2022.07.018
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....9d32d9e1faa11dc016befcd399fb6dc3
قاعدة البيانات: OpenAIRE